Chemical ecology and convergent evolution of natural hallucinogens: From ecological defense to conserved neural targets
Yibo Wang, H Wang, C T Lin, Xiaohui Wang
Proceedings of the National Academy of Sciences June 24, 2026 DOI: 10.1073/pnas.2535785123 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Mescaline Psilocybin |
| Keywords | Convergent evolution Chemical ecology Functional ecology Chemical biology Comparative biology Function biology Hallucinogen Evolutionary biology Comparative genomics Natural archaeology Cognitive science |
| Key points | Proposes that natural hallucinogens evolved primarily as ecological agents (defense or symbiosis) and that human psychoactivity is an evolutionary by-product of their action on conserved neural targets. |
Abstract
Natural hallucinogenic compounds have arisen independently across plants, fungi, and animals, evolving into a diverse chemical arsenal that includes phenethylamines, indolealkylamines, and terpenoid scaffolds. Beyond clinical and cultural frameworks, their ecological origins and evolutionary trajectories may help explain why such potent modulators of perception, emotion, and cognition persist in nature. Here, integrating chemical ecology, comparative genomics, biosynthetic logic, and evolutionary biology, we propose that these molecules may function as defensive agents or symbiosis-associated manipulators of herbivore and pollinator behavior. A "building-block" biosynthetic logic links primary metabolism to convergent psychotropic scaffolds via a recurrent set of tailoring reactions, including decarboxylations and methylations. Recent advances illuminate mescaline biosynthesis in cacti, horizontal gene transfer of psilocybin clusters in fungi, and symbiont-derived alkaloids in grasses. We also assess the debate surrounding endogenous mammalian tryptamines, arguing that the leading hypothesis points toward sigma-1 receptor-mediated cytoprotection and stress responses, supported by convergent pharmacological and cellular evidence, rather than inherent hallucinogenic functions. Across kingdoms, natural hallucinogens appear to converge on conserved neural targets, including serotonergic and other neuromodulatory systems that are shared across phyla. From this perspective, human psychoactivity is likely an evolutionary by-product of molecules selected for ecological interactions with animals possessing deeply conserved receptor architectures. Framing hallucinogens through chemical ecology not only clarifies their origins but also highlights translational opportunities in target discovery, pathway engineering, and sustainable production, while emphasizing the need to integrate conservation, ethical sourcing, and benefit-sharing into the current hallucinogenic renaissance.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
State of the evidence: Mescaline Unclear
Proposes that natural hallucinogens evolved primarily as ecological agents and that human psychoactivity is an evolutionary by-product of their action on conserved neural targets, noting advances in understanding mescaline biosynthesis in cacti.
Synthesized
Comparable studies
Other theoretical and historical papers on mescaline, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Schizophrenia: A New Approach. II. Result of a Year's Research | 1954 | Theoretical or philosophical paper | |
| Thought insertion as a self-disturbance: An integration of predictive coding and phenomenological approaches | 2016 | Theoretical or philosophical paper | |
| Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated | 2022 | Theoretical or philosophical paper | |
| Steric and Electronic Relationships among Some Hallucinogenic Compounds | 1970 | Theoretical or philosophical paper | |
| EFFECT OF DRUGS One individual | 1952 | Theoretical or philosophical paper | n = 1 |
Citations in the library
Cites 56
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
and 51 more in the library